（原标题：和黄医药（00013.HK）2025年财报：财务和业务显着进展）金吾财讯|和黄医药（00013.HK）在2025年取得了显着的财务和业务进展。公司在肿瘤和免疫领域的创新药物研发和商业化方面取得了多项重要成果，同时在财务表现上也有了显着提升。 财报显示，和黄医药2025年的收入总额为548.5百万美元，同比下降13%。毛利为256.8百万美元，同比微增0.6%。经营盈利为498.7百万美元...
Source Link（原标题：和黄医药（00013.HK）2025年财报：财务和业务显着进展）金吾财讯|和黄医药（00013.HK）在2025年取得了显着的财务和业务进展。公司在肿瘤和免疫领域的创新药物研发和商业化方面取得了多项重要成果，同时在财务表现上也有了显着提升。 财报显示，和黄医药2025年的收入总额为548.5百万美元，同比下降13%。毛利为256.8百万美元，同比微增0.6%。经营盈利为498.7百万美元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.